3 days ago · Robert Mach on A positron emission tomography tracer for the imaging of oxidative stress in the central nervous system. 11 Mar 2025; Pierre Tariot on Sex Differences in Blood of Alzheimer’s and Parkinson’s Patients 11 Mar 2025; Michal Schwartz on With Age, Macrophages Chew up the Blood-CSF Barrier 10 Mar 2025; Charles Stromeyer on Can Autoimmunity Spark Alzheimer’s Disease? 10 Mar 2025

Overview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...

AlzAntibodies. This database aims to provide detailed descriptions of selected antibodies related to the study of Alzheimer’s disease. AlzBiomarker

Aug 17, 2020 · Overview. Name: Kisunla Synonyms: Donanemab, LY3002813, N3pG-Aβ Monoclonal Antibody Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic drug recognizes ...

AlzGene is a collection of published Alzheimer's disease genetic association studies, with random-effects meta-analyses for polymorphisms with genotype data in at least three case-control samples.

Oct 9, 2023 · Papers. Gauthier S, Molinuevo JL.Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 2012 Oct 27; PubMed.; Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T.

View our conference coverage. Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

Overview. Name: Mivelsiran Synonyms: ALN-APP Therapy Type: DNA/RNA-based Target Type: Amyloid-Related Condition(s): Alzheimer's Disease, Cerebral Amyloid Angiopathy U.S. FDA Status: Alzheimer's Disease (Phase 1), Cerebral Amyloid Angiopathy (Phase 2) Company: Alnylam Pharmaceuticals, Inc. Background. This gene-silencing approach uses intrathecal injection of a small interfering RNA targeting ...

Aug 5, 2024 · Overview. Name: VG-3927 Therapy Type: Small Molecule Target Type: Amyloid-Related , Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 1) Company: Vigil Neuroscience, Inc. Background. VG-3927 is a brain-penetrant, small-molecule agonist of the TREM2 receptor on microglia. TREM2 activation stimulates proliferation and phagocytic function of microglia ...

Oct 16, 2024 · Overview. Name: Minzasolmin Synonyms: UCB0599, NPT200-11 Chemical Name: N-[(2R)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide Therapy Type: Small Molecule Target Type: alpha-synuclein Condition(s): Parkinson's Disease U.S. FDA Status: Parkinson's Disease (Phase 2) Company: Neuropore Therapies, Inc., Novartis Pharmaceuticals Corporation, UCB S.A.